- Follow-up data from a Phase 1/2 clinical trial, CheckMate-032, evaluating Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) + Yervoy (ipilimumab) in patients with platinum-resistant metastatic urothelial carcinoma (advanced form of bladder cancer) showed a positive treatment effect. The results were presented at ESMO in Munich.
- At a minimum follow-up of 7.9 months, patients receiving 1 mg/kg of Opdivo and 3 mg/kg of Yervoy (O1:Y3) showed an overall response rate (ORR) of 38%. At a minimum follow-up of 38.8 months, patients receiving 3 mg/kg of Opdivo and 1 mg/kg of Yervoy (O3:Y1) showed an ORR of 27%. At a minimum follow-up of 37.7 months, patients receiving Opdivo alone showed an ORR of 26%.
- Median progression-free survival (PFS) and overall survival (OS) in the three arms were 4.9 months and 15.3 months, 2.6 months and 7.4 months and 2.8 months and 9.9 months, respectively.
- No new safety signals were observed.
- The data support the ongoing Phase 3 CheckMate-901 study in treatment-naive bladder cancer patients.
- #ESMO